Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Folashade Otegbeye
Observed names:
F Otegbeye,
F. Otegbeye,
FM Otegbeye,
FOLASHADE otegbeye
Institution:
Fred Hutch Cancer Center
Observed institutions:
Cleveland Clinic,
University of Washington,
University Hospitals of Cleveland,
Fred Hutch Cancer Center,
University Hospitals Cleveland Medical Center,
University Hospitals Seidman Cancer Center,
Case Comprehensive Cancer Center,
Case Western Reserve University
show all 8
ORCID:
0000-0002-9978-4719
Observed ORCID:
0000-0002-9978-4719
OpenAlex ID:
A5062918970
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
2023
·
Srdan Verstovsek
, Aaron T Gerds
, et al.
·
The Lancet
·
217
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
2018
·
Folashade Otegbeye
, Evelyn Ojo
, et al.
·
PLoS ONE
·
149
PDF
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
2019
·
Evelyn O. Ojo
, Ashish Arunkumar Sharma
, et al.
·
Scientific Reports
·
130
PDF
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
2021
·
Paolo F. Caimi
, Gabriela Pacheco Sanchez
, et al.
·
Frontiers in Immunology
·
127
PDF
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
2021
·
Michael Maschan
, Paolo F. Caimi
, et al.
·
Nature Communications
·
96
PDF
Perioperative Management of Sickle Cell Disease: a Narrative Review
2018
·
Kwame Ofori Adjepong
, Folashade Otegbeye
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
58
PDF
Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study
2019
·
Najla El Jurdi
, Ali Filali-Mouhim
, et al.
·
Transplantation and Cellular Therapy
·
50
Socioeconomic Factors and Survival of Multiple Myeloma Patients
2021
·
Kamal Chamoun
, Amin Firoozmand
, et al.
·
Cancers
·
35
PDF
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
2024
·
Leland L. Metheny
, Ronald Sobecks
, et al.
·
Blood Advances
·
34
PDF
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors
2022
·
Folashade Otegbeye
, Brenda Cooper
, et al.
·
Transplantation and Cellular Therapy
·
32
PDF
Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms
2023
·
Jennifer N. Saultz
, Folashade Otegbeye
·
Frontiers in Immunology
·
31
PDF
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models
2020
·
Gouri Dharmavaram
, Shufen Cao
, et al.
·
American Journal of Hematology
·
24
PDF
Development and validation of predictive models of early immune effector cell–associated hematotoxicity
2024
·
Emily C. Liang
, Jennifer J. Huang
, et al.
·
Blood Advances
·
17
PDF
Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
2018
·
Folashade Otegbeye
, Evelyn Ojo
, et al.
·
PLoS ONE
·
17
PDF
Autologous GVHD?
2014
·
F Otegbeye
, R P Gale
, et al.
·
Bone Marrow Transplantation
·
16
PDF
CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity
2020
·
Paolo F Caimi
, Ashish Sharma
, et al.
·
Blood
·
15
Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy
2020
·
Nausheen Ahmed
, Paolo Caimi
, et al.
·
Transplantation and Cellular Therapy
·
14
Creating a GMP cell processing program: A focus on quality and regulation
2025
·
Darshan Patel
, Jane Reese Koç
, et al.
·
Best Practice & Research Clinical Haematology
·
13
Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation
2017
·
Anand Tandra
, Fahrettin Covut
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
13
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse
2018
·
Masumi Ueda
, Najla El-Jurdi
, et al.
·
Transplantation and Cellular Therapy
·
12
PDF
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up
2025
·
Andrew J. Portuguese
, Jennifer J. Huang
, et al.
·
Haematologica
·
11
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
2025
·
Armin Ghobadi
, Paolo F. Caimi
, et al.
·
EClinicalMedicine
·
11
Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation
2020
·
Lucy Li
, Merle Kolk
, et al.
·
Bone Marrow Transplantation
·
11
PDF
Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure
2020
·
Julianne N.P. Smith
, Folashade Otegbeye
, et al.
·
Transplantation and Cellular Therapy
·
11
PDF
Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
2024
·
Andrew J. Portuguese
, Aya Albittar
, et al.
·
Transplantation and Cellular Therapy
·
9
Show more works
View as search
Works count:
120
Citation count:
1,326
H-index:
15
I10-index:
24
Year
Topic
Type
